Investigative Ophthalmology & Visual Science, Vol 37, 1204-1208, Copyright © 1996 by Association for Research in Vision and Ophthalmology

ARTICLES AND REPORTS

Human trabecular meshwork cell survival is dependent on perfusion rate

DH Johnson
Department of Ophthalmology, Mayo Clinic 55905, USA.

PURPOSE. To determine whether suppression of flow may be detrimental to trabecular cell survival and to the morphologic characteristics of the trabecular meshwork. METHODS. The anterior segments of normal human eye bank eyes were placed in perfusion organ culture. The effect of various perfusion rates of culture medium, and of the constant flow and constant pressure methods of delivery of culture medium, were studied. Trabecular cell survival was determined by quantitation of cell nuclei in histologic sections and by morphologic observation. RESULTS. Trabecular meshworks with perfusion rates of 1 microliter/minute and higher had significantly more trabecular cells than meshworks with lower perfusion rates. A significant loss of trabecular cells was found in meshworks cultured with the constant pressure technique when compared with fellow eyes cultured with the constant flow of medium. Those constant pressure cultured meshworks with surviving cells had higher flow rates than those with necrotic cells. CONCLUSIONS. A minimum perfusion rate of 1 microliter/minute is required for trabecular cell survival in perfusion organ culture. Constant pressure perfusion of medium is unsuccessful in maintaining trabecular cells in long-term culture if low perfusion rates occur. Constant flow appears to mimic the in vivo situation more closely.

This article has been cited by other articles:

				R. F. Ramos and W. D. Stamer Effects of Cyclic Intraocular Pressure on Conventional Outflow Facility Invest. Ophthalmol. Vis. Sci., January 1, 2008; 49(1): 275 - 281. [Abstract] [Full Text] [PDF]

				C. K. Bahler, M. P. Fautsch, C. R. Hann, and D. H. Johnson Factors Influencing Intraocular Pressure in Cultured Human Anterior Segments Invest. Ophthalmol. Vis. Sci., September 1, 2004; 45(9): 3137 - 3143. [Abstract] [Full Text] [PDF]

				C. K. Bahler, C. R. Hann, M. P. Fautsch, and D. H. Johnson Pharmacologic Disruption of Schlemm's Canal Cells and Outflow Facility in Anterior Segments of Human Eyes Invest. Ophthalmol. Vis. Sci., July 1, 2004; 45(7): 2246 - 2254. [Abstract] [Full Text] [PDF]

				C. R. Ethier, S. Wada, D. Chan, and W. D. Stamer Experimental and Numerical Studies of Adenovirus Delivery to Outflow Tissues of Perfused Human Anterior Segments Invest. Ophthalmol. Vis. Sci., June 1, 2004; 45(6): 1863 - 1870. [Abstract] [Full Text] [PDF]

				J. Gottanka, D. Chan, M. Eichhorn, E. Lutjen-Drecoll, and C. R. Ethier Effects of TGF-{beta}2 in Perfused Human Eyes Invest. Ophthalmol. Vis. Sci., January 1, 2004; 45(1): 153 - 158. [Abstract] [Full Text] [PDF]

				A. J. Santas, C. Bahler, J. A. Peterson, M. S. Filla, P. L. Kaufman, E. R. Tamm, D. H. Johnson, and D. M. P. Peters Effect of Heparin II Domain of Fibronectin on Aqueous Outflow in Cultured Anterior Segments of Human Eyes Invest. Ophthalmol. Vis. Sci., November 1, 2003; 44(11): 4796 - 4804. [Abstract] [Full Text] [PDF]

				T. Borras, L. L. S. Rowlette, E. R. Tamm, J. Gottanka, and D. L. Epstein Effects of Elevated Intraocular Pressure on Outflow Facility and TIGR/MYOC Expression in Perfused Human Anterior Segments Invest. Ophthalmol. Vis. Sci., January 1, 2002; 43(1): 33 - 40. [Abstract] [Full Text] [PDF]

				M. P. Fautsch, C. K. Bahler, D. J. Jewison, and D. H. Johnson Recombinant TIGR/MYOC Increases Outflow Resistance in the Human Anterior Segment Invest. Ophthalmol. Vis. Sci., December 1, 2000; 41(13): 4163 - 4168. [Abstract] [Full Text]

				P. Gonzalez, D. L. Epstein, and T. Borrás Characterization of Gene Expression in Human Trabecular Meshwork Using Single-Pass Sequencing of 1060 Clones Invest. Ophthalmol. Vis. Sci., November 1, 2000; 41(12): 3678 - 3693. [Abstract] [Full Text]

				P. Gonzalez, D. L. Epstein, and T. Borrás Genes Upregulated in the Human Trabecular Meshwork in Response to Elevated Intraocular Pressure Invest. Ophthalmol. Vis. Sci., February 1, 2000; 41(2): 352 - 361. [Abstract] [Full Text]